XNCR Quote, Financials, Valuation and Earnings

Bristol Myers Squibb Co. has a net margin of -28.7% compared to Xencor, Inc.'s net margin of 8.69%. Xencor, Inc.'s return on equity of -20.07% beat Bristol Myers Squibb Co.'s return on equity of 39.9%.

Xencor, Inc. has a consensus price target of $28.83, signalling upside risk potential of 148.78%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $59.91 which suggests that it could fall by -1.36%. Given that Xencor, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Xencor, Inc. is more attractive than Bristol Myers Squibb Co..

Xencor, Inc. has a beta of 0.980, which suggesting that the stock is 1.968% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.287, suggesting its less volatile than the S&P 500 by 71.296%.

Xencor, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.1% to investors and pays a quarterly dividend of $0.63 per share. Xencor, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 71.98% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Xencor, Inc. quarterly revenues are $21M, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.5B. Xencor, Inc.'s net income of -$6M is lower than Bristol Myers Squibb Co.'s net income of $1.1B. Notably, Xencor, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 17.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor, Inc. is 5.70x versus 2.57x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

MacroGenics, Inc. has a net margin of -28.7% compared to Xencor, Inc.'s net margin of 23.1%. Xencor, Inc.'s return on equity of -20.07% beat MacroGenics, Inc.'s return on equity of -88.47%.

Xencor, Inc. has a consensus price target of $28.83, signalling upside risk potential of 148.78%. On the other hand MacroGenics, Inc. has an analysts' consensus of $3.40 which suggests that it could grow by 98.83%. Given that Xencor, Inc. has higher upside potential than MacroGenics, Inc., analysts believe Xencor, Inc. is more attractive than MacroGenics, Inc..

Xencor, Inc. has a beta of 0.980, which suggesting that the stock is 1.968% less volatile than S&P 500. In comparison MacroGenics, Inc. has a beta of 1.505, suggesting its more volatile than the S&P 500 by 50.537%.

Xencor, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MacroGenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor, Inc. pays -- of its earnings as a dividend. MacroGenics, Inc. pays out -- of its earnings as a dividend.

Xencor, Inc. quarterly revenues are $21M, which are smaller than MacroGenics, Inc. quarterly revenues of $72.8M. Xencor, Inc.'s net income of -$6M is lower than MacroGenics, Inc.'s net income of $16.8M. Notably, Xencor, Inc.'s price-to-earnings ratio is -- while MacroGenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor, Inc. is 5.70x versus 0.84x for MacroGenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -28.7% compared to Xencor, Inc.'s net margin of 18.06%. Xencor, Inc.'s return on equity of -20.07% beat Merck & Co., Inc.'s return on equity of 39.63%.

Xencor, Inc. has a consensus price target of $28.83, signalling upside risk potential of 148.78%. On the other hand Merck & Co., Inc. has an analysts' consensus of $124.88 which suggests that it could grow by 2.86%. Given that Xencor, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Xencor, Inc. is more attractive than Merck & Co., Inc..

Xencor, Inc. has a beta of 0.980, which suggesting that the stock is 1.968% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Xencor, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.7% to investors and pays a quarterly dividend of $0.85 per share. Xencor, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Xencor, Inc. quarterly revenues are $21M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Xencor, Inc.'s net income of -$6M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Xencor, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor, Inc. is 5.70x versus 4.68x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -28.7% compared to Xencor, Inc.'s net margin of -9.34%. Xencor, Inc.'s return on equity of -20.07% beat Pfizer Inc.'s return on equity of 10.84%.

Xencor, Inc. has a consensus price target of $28.83, signalling upside risk potential of 148.78%. On the other hand Pfizer Inc. has an analysts' consensus of $28.63 which suggests that it could grow by 3.8%. Given that Xencor, Inc. has higher upside potential than Pfizer Inc., analysts believe Xencor, Inc. is more attractive than Pfizer Inc..

Xencor, Inc. has a beta of 0.980, which suggesting that the stock is 1.968% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Xencor, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.24% to investors and pays a quarterly dividend of $0.43 per share. Xencor, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

Xencor, Inc. quarterly revenues are $21M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Xencor, Inc.'s net income of -$6M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Xencor, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 20.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor, Inc. is 5.70x versus 2.51x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.